Abstract
On the basis of preclinical data suggesting the possibility of maximising the efficacy of 5-fluorouracil and cisplatin by interferon, a pilot clinical trial was initiated in recurrent and/or metastatic head and neck cancer. Thirty-four patients were treated with cisplatin at 100 mg m-2, followed by 5-fluorouracil at 1,000 mg m-2 by continuous infusion for 5 days. Interferon alpha 2b was administered at the dose of 3 million U i.m. daily for 7 days, beginning the day before chemotherapy. Courses were repeated every 3 weeks. Two patients achieved a complete remission, six a partial response, 14 had stable disease and 12 progressed on therapy, for an overall response rate of 23% (95% confidence interval 10-36%). Median survival time was 5 months. Toxicity was severe. Stomatitis, diarrhoea and myelosuppression were the most common side-effects. Because of the poor response rate and the presence of severe toxicity, in our opinion further clinical trials in head and neck cancer should be attempted only after a better definition in preclinical studies of interactions among 5-fluorouracil, cisplatin and interferon.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol. 1988 Feb;15(1):70–85. [PubMed] [Google Scholar]
- Lin S. L., Kikuchi T., Pledger W. J., Tamm I. Interferon inhibits the establishment of competence in Go/S-phase transition. Science. 1986 Jul 18;233(4761):356–359. doi: 10.1126/science.3726533. [DOI] [PubMed] [Google Scholar]
- Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Vokes E. E., Choi K. E., Schilsky R. L., Moran W. J., Guarnieri C. M., Weichselbaum R. R., Panje W. R. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr;6(4):618–626. doi: 10.1200/JCO.1988.6.4.618. [DOI] [PubMed] [Google Scholar]
- Vokes E. E., Ratain M. J., Mick R., McEvilly J. M., Haraf D., Kozloff M., Hamasaki V., Weichselbaum R. R., Panje W. R., Wenig B. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb;11(2):360–368. doi: 10.1200/JCO.1993.11.2.360. [DOI] [PubMed] [Google Scholar]
- Vokes E. E., Schilsky R. L., Weichselbaum R. R., Kozloff M. F., Panje W. R. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb;8(2):241–247. doi: 10.1200/JCO.1990.8.2.241. [DOI] [PubMed] [Google Scholar]
- Wadler S., Schwartz E. L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990 Jun 15;50(12):3473–3486. [PubMed] [Google Scholar]